California’s unique effort to create low-cost insulins survived state budget cuts this year, but it remains unclear when cheaper medications will reach thousands of state residents.
Insulin created for the state’s CalRx label won’t get Food and Drug Administration approval in 2024, according to state officials, and $50 million in funding for the program has been deferred to mid-2025. The state agency overseeing the initiative, however, says the nonprofit group contracted to manufacture the drugs, Civica, has been in talks with federal regulators about the approval process.
Civica “has a clear path forward” following recent meetings with the FDA, Andrew ...